Disease · MONDO_0015925
Comparisons in its trials28
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 28
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Inhaled Treprostinil vs Placebo: Incidence of Clinical Worsening | 37 of 163 | 54 of 163 | 326 | NCT02630316 | Trial comparisons |
| Active Inhaled Treprostinil vs Placebo: deaths from any cause | 10 of 163 | 12 of 163 | 326 | NCT02630316 | Trial comparisons |
| Active Inhaled Treprostinil vs Placebo: serious adverse events | 38 of 163 | 42 of 163 | 326 | NCT02630316 | Trial comparisons |
| Pirfenidone vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 120 of 127 | 101 of 124 | 251 | NCT03099187 | Trial comparisons |
| Cylophosphamide vs Placebo: serious adverse events | 5 of 79 | 5 of 79 | 158 | NCT00004563 | Trial comparisons |
| Mycophenolate Arm vs Cyclophosphamide Arm: serious adverse events | 27 of 69 | 22 of 73 | 142 | NCT00883129 | Trial comparisons |
| Pirfenidone vs Placebo: Hospitalization for Respiratory Cause | 2 of 63 | 5 of 60 | 123 | NCT02808871 | Trial comparisons |
| Pirfenidone vs Placebo: Number of Participants Who Developed Any Element of the Composite Endpoint | 7 of 63 | 9 of 60 | 123 | NCT02808871 | Trial comparisons |
| Pirfenidone vs Placebo: All-cause Mortality | 2 of 63 | 3 of 60 | 123 | NCT02808871 | Trial comparisons |
| Pirfenidone vs Placebo: Number of Participants With Progressive Disease | 16 of 63 | 19 of 60 | 123 | NCT02808871 | Trial comparisons |
| Pirfenidone vs Placebo: All Cause Hospitalization | 7 of 63 | 7 of 60 | 123 | NCT02808871 | Trial comparisons |
| Pirfenidone vs Placebo: Acute Exacerbations Requiring Hospitalization | 1 of 63 | 2 of 60 | 123 | NCT02808871 | Trial comparisons |
| Pirfenidone vs Placebo: deaths from any cause | 2 of 63 | 3 of 60 | 123 | NCT02808871 | Trial comparisons |
| Pirfenidone vs Placebo: Number of Participants With FVC Decline From Baseline of 10% or Greater | 5 of 63 | 7 of 60 | 123 | NCT02808871 | Trial comparisons |
| Pirfenidone vs Placebo: Treatment-emergent/Treatment-related SAEs | 1 of 62 | 0 of 60 | 122 | NCT02808871 | Trial comparisons |
| Pirfenidone vs Placebo: Treatment-emergent Death or Transplant | 2 of 62 | 4 of 60 | 122 | NCT02808871 | Trial comparisons |
| Pirfenidone vs Placebo: Treatment-emergent/Treatment-related AEs | 27 of 62 | 18 of 60 | 122 | NCT02808871 | Trial comparisons |
| Pirfenidone vs Placebo: AEs Leading to Early Discontinuation of Study Treatment | 15 of 62 | 6 of 60 | 122 | NCT02808871 | Trial comparisons |
| Pirfenidone vs Placebo: Treatment-emergent Serious Adverse Events (SAEs) | 9 of 62 | 8 of 60 | 122 | NCT02808871 | Trial comparisons |
| Pirfenidone vs Placebo: Treatment-emergent Adverse Events (AEs) | 62 of 62 | 56 of 60 | 122 | NCT02808871 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015925/comparisons